Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
19.84
+0.10 (0.48%)
At close: May 16, 2025, 4:00 PM
20.12
+0.29 (1.44%)
After-hours: May 16, 2025, 5:40 PM EDT
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Rigel Pharmaceuticals stock ranges from a low of $23 to a high of $57. The average analyst price target of $36.4 forecasts a 83.51% increase in the stock price over the next year.
Price Target: $36.40 (+83.51%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rigel Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | +15.96% | May 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +177.29% | Mar 6, 2025 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $20 → $24 | Hold | Maintains | $20 → $24 | +21.00% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +187.37% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +187.37% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
223.12M
from 179.28M
Increased by 24.45%
Revenue Next Year
239.26M
from 223.12M
Increased by 7.23%
EPS This Year
1.06
from 0.99
Increased by 7.07%
EPS Next Year
1.76
from 1.06
Increased by 66.44%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 261.5M | 273.5M | 294.0M | ||
| Avg | 223.1M | 239.3M | 268.5M | ||
| Low | 185.0M | 217.2M | 245.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.9% | 22.6% | 22.9% | ||
| Avg | 24.5% | 7.2% | 12.2% | ||
| Low | 3.2% | -2.7% | 2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.39 | 3.45 | 6.03 | ||
| Avg | 1.06 | 1.76 | 3.51 | ||
| Low | 0.69 | 0.66 | 1.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0% | 225.8% | 241.7% | ||
| Avg | 7.1% | 66.4% | 99.2% | ||
| Low | -30.7% | -38.1% | -36.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.